Profound Medical Expands TULSA-PRO® Distribution to Australia and New Zealand

Profound Medical has formed a strategic distribution agreement with Getz Healthcare to introduce its advanced TULSA-PRO® technology to Australia and New Zealand. This partnership aims to make the cutting-edge prostate health treatment more accessible in these regions, potentially transforming healthcare outcomes for patients with prostate conditions.

Profound Medical, known for its innovative therapeutic technologies, is expanding its reach through a collaboration with Getz Healthcare. The TULSA-PRO® is a groundbreaking transurethral ultrasound ablation system designed to provide a minimally invasive option for prostate treatment. By partnering with Getz Healthcare, a well-respected entity in the Asia Pacific healthcare market, Profound Medical aims to leverage Getz’s extensive regional expertise to better serve the medical community in Australia and New Zealand. This move is significant as the demand for advanced prostate treatment solutions continues to rise, driven by an increasing incidence of prostate health issues globally. The TULSA-PRO® offers unique advantages such as precision targeting of the prostate tissue and minimized damage to surrounding organs, which can lead to improved patient outcomes.